Results 41 to 50 of about 3,286,390 (370)
T-Cell Therapy of Leukemia [PDF]
Cancer Control, 2002 The demonstration that immune-mediated elimination of leukemia contributes to the success of allogeneic hematopoietic stem cell transplantation (HSCT) has renewed interest in the development of immune-based therapies that might be used to augment the antileukemic effect of HSCT or in patients who are not receiving HSCT.The authors reviewed studies that
Stanley R. Riddell +3 more
openaire +3 more sources
Two-year follow-up of macaques developing intermittent control of the human immunodeficiency virus homolog simian immunodeficiency virus SIVmac251 in the chronic phase of infection [PDF]
, 2015 Off-therapy control of viremia by HIV-infected individuals has been associated with two likely players: a restricted viral reservoir and an efficient cell-mediated immune response.
Arts, Eric +14 more
core +2 more sources
Computational model for tumor response to adoptive cell transfer therapy [PDF]
arXiv, 2022 One of the barriers to the development of effective adoptive cell transfer therapies (ACT), specifically for genetically engineered T-cell receptors (TCRs), and chimeric antigen receptor (CAR) T-cells, is target antigen heterogeneity. It is thought that intratumor heterogeneity is one of the leading determinants of therapeutic resistance and treatment ...
arxiv
T-cell therapy at the threshold [PDF]
Nature Biotechnology, 2012 Despite impressive clinical activity in B-cell lymphoma and melanoma, questions remain about the immunobiology of adoptive T-cell therapies.
Steven A. Rosenberg +3 more
openaire +3 more sources
Scientific Reports, 2021 Extracellular vesicles (EVs) have attracted interest due to their ability to provide diagnostic information from liquid biopsies. Cells constantly release vesicles divers in size, content and features depending on the biogenesis, origin and function ...
Susann Allelein +6 more
doaj +1 more source
Simulating the Evolution of Signaling Signatures during CART-Cell -- Tumor Cell Interactions [PDF]
arXiv, 2023 Immunotherapies have been proven to have significant therapeutic efficacy in the treatment of cancer. The last decade has seen adoptive cell therapies, such as chimeric antigen receptor T-cell (CART-cell) therapy, gain FDA approval against specific cancers.
arxiv
Cell Therapy: Replacement [PDF]
Stroke, 2003 Not long ago, the ability of the brain to restore function through regeneration of neural elements was thought to be nonexistent. It is now known that not only does some regenerative capacity exist, but implanted cells can integrate into the host brain, survive, and reverse neurological deficits.
Lawrence R. Wechsler, Douglas Kondziolka
openaire +3 more sources
Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients [PDF]
, 2015 Natural Killer (NK) cells are a key component of tumor immunosurveillance and thus play an important role in rituximab-dependent killing of lymphoma cells via an antibody-dependent cellular cytotoxicity (ADCC) mechanism.
Battella, Simone +13 more
core +1 more source
Stochastic multi-scale models of competition within heterogeneous cellular populations: simulation methods and mean-field analysis [PDF]
, 2016 We propose a modelling framework to analyse the stochastic behaviour of heterogeneous, multi-scale cellular populations. We illustrate our methodology with a particular example in which we study a population with an oxygen-regulated proliferation rate ...
Alarcón, Tomás +3 more
core +6 more sources
Molecular Cancer, 2023 Background Chimeric Antigen Receptor (CAR) T cells are now standard of care (SOC) for some patients with B cell and plasma cell malignancies and could disrupt the therapeutic landscape of solid tumors.
Hyatt Balke-Want +16 more
doaj +1 more source